EC Ophthalmology

Objective: To explore the ophthalmopathy induced by COVID-19 Yangkang.

Methods: From February to May 2023 in the outpatient department, of 8 diseases (20 cases) induced by COVID-19 Yangkang were investigated. After diagnosis, antiviral and symptomatic treatment will be given, along with medication that supplements eye tissue depending on the condition. In severe cases, temporary use of hormones throughout the body can improve the patient's temporary immune emergency response ability; Individual patients are given prophylactic antibiotics to prevent secondary bacterial infections.

Result: As a result, the condition was quickly brought under control and recovered.

Conclusion: After COVID-19 Yangkang, COVID-19 has not been completely eliminated in vivo. COVID-19 does not only invade the lung tissue, it can invade the eyes with blood, nerves, lacrimal passages and other ways, causing diseases such as fundus, uvea, ophthalmic nerve, and eye surface, causing serious damage to the eyes, and even the risk of blindness. It should be highly valued in ophthalmic clinical practice.

Keywords: COVID-19; Yangkang Hou; Eye Disease

1. Jeong GU., et al. “Ocular tropism of SARS-CoV-2 in animal models with retinal inflammation via neuronal invasion following intranasal inoculation”. Nature Communications 1 (2022): 7675.
2. Yoonjung Kim., et al. “Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID”. Journal of Infection and Chemotherapy 3 (2022): 566-597.
3. Jilian Dong., et al. “COVID-19 and ocular complications: A review of ocular manifestations, diagnostic tools, and prevention strategies”. Advances in Ophthalmology Practice and Research 1 (2022): 33-38.
4. Armstrong L., et al. “In the eye of the storm: SARS-CoV-2 infection and replication at the ocular surface?”. Stem Cells Translational Medicine 7 (2021): 976-986.
5. Casagrande M., et al. “Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients”. Ocular Immunology and Inflammation 5 (2020): 721-725.
6. Adler H., et al. “Low rate of bacterial coinfection in patients with COVID-19”. The Lancet Microbe 2 (2020): e62.
7. Rokohl AC., et al. “More than loss of taste and smell: burning watering eyes in coronavirus disease 2019”. Clinical Microbiology and Infection 11 (2020): 1565-1568.
8. Bourdon H., et al. “Teleconsultation in primary ophthalmic emergencies during the COVID-19 lockdown in Paris: Experience with 500 patients in March and April 2020”. Journal Français d'Ophtalmologie 7 (2020): 577-585.
9. Chen L., et al. “Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease”. British Journal of Ophthalmology6 (2020): 748-751.
10. Public Health Ophthalmology Branch of Chinese Preventive Medicine Association. “Expert consensus on the prevention and control of novel coronavirus eye diseases in China”. Chinese Journal of Ophthalmology3 (2022): 176-181.
11. Shao Yi and Shi Wenqing. “American Ophthalmology Society dry eye guideline interpretation”. New Progress in Ophthalmology12 (2019): 1101-1104+10.
12. Casagrande M., et al. “Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients”. Ocular Immunology and Inflammation5 (2020): 721-725.
13. Li JO., et al. “Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear”. British Journal of Ophthalmology3 (2020): 297-298.